Title / AuthorYear
Pharmaceutical cocrystals: walking the talk
G Bolla, A Nangia
Chemical communications 52 (54), 8342-8360
2016
Towards medicinal mechanochemistry: evolution of milling from pharmaceutical solid form screening to the synthesis of active pharmaceutical ingredients (APIs)
D Tan, L Loots, T Friščić
Chemical Communications 52 (50), 7760-7781
2016
Pharmaceutical cocrystals, salts and multicomponent systems; intermolecular interactions and property based design
DJ Berry, JW Steed
Advanced drug delivery reviews 117, 3-24
2017
Engineering and manufacturing of pharmaceutical co-crystals: a review of solvent-free manufacturing technologies
SA Ross, DA Lamprou, D Douroumis
Chemical Communications 52 (57), 8772-8786
2016
Crystal engineering of hand-twisted helical crystals
S Saha, GR Desiraju
Journal of the American Chemical Society 139 (5), 1975-1983
2017
Time for pairing: cocrystals as advanced energetic materials
J Zhang
CrystEngComm 18 (33), 6124-6133
2016
Supramolecular organic frameworks: engineering periodicity in water through host–guest chemistry
J Tian, L Chen, DW Zhang, Y Liu, ZT Li
Chemical Communications 52 (38), 6351-6362
2016
Pharmaceutical aspects of salt and cocrystal forms of APIs and characterization challenges
PC Vioglio, MR Chierotti, R Gobetto
Advanced drug delivery reviews 117, 86-110
2017
Screening for new pharmaceutical solid forms using mechanochemistry: A practical guide
D Hasa, W Jones
Advanced drug delivery reviews 117, 147-161
2017
Co-crystallization and small molecule crystal form diversity: from pharmaceutical to materials applications
S Cherukuvada, R Kaur, TNG Row
CrystEngComm 18 (44), 8528-8555
2016
Machine learning for the structure–energy–property landscapes of molecular crystals
F Musil, S De, J Yang, JE Campbell, GM Day, M Ceriotti
Chemical science 9 (5), 1289-1300
2018
Creating cocrystals: a review of pharmaceutical cocrystal preparation routes and applications
M Karimi-Jafari, L Padrela, GM Walker, DM Croker
Crystal Growth & Design 18 (10), 6370-6387
2018
Improving the solubility and bioavailability of apixaban via apixaban–oxalic acid cocrystal
Y Chen, L Li, J Yao, YY Ma, JM Chen, TB Lu
Crystal Growth & Design 16 (5), 2923-2930
2016
Cocrystal and salt forms of furosemide: solubility and diffusion variations
M Banik, SP Gopi, S Ganguly, GR Desiraju
Crystal Growth & Design 16 (9), 5418-5428
2016
Co-Crystal of Tramadol hydrochloride–Celecoxib (CTC): a novel API–API co-crystal for the treatment of pain
C Almansa, R Merce, N Tesson, J Farran, J Tomàs, CR Plata-Salaman
Crystal Growth & Design 17 (4), 1884-1892
2017
Recent developments in the crystallization process: toward the pharmaceutical industry
Z Gao, S Rohani, J Gong, J Wang
Engineering 3 (3), 343-353
2017
The need for restructuring the disordered science of amorphous drug formulations
K Edueng, D Mahlin, CAS Bergström
Pharmaceutical research 34 (9), 1754-1772
2017
Challenges in translational development of pharmaceutical cocrystals
DP Kale, SS Zode, AK Bansal
Journal of pharmaceutical sciences 106 (2), 457-470
2017
A practical guide to the design of molecular crystals
MK Corpinot, DK Bučar
Crystal Growth & Design 19 (2), 1426-1453
2018
Experimental cocrystal screening and solution based scale-up cocrystallization methods
M Malamatari, SA Ross, D Douroumis, SP Velaga
Advanced drug delivery reviews 117, 162-177
2017
1 - 20
Dates and citation counts are estimated and are determined automatically by a computer program.